# Test Results: literature/paper-summary.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/paper-summary.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am a microbiome researcher reviewing literature on diet-microbiome interactions. I need a structured summary of the following paper for my literature notes.

Paper text:
[SIMULATED PAPER EXCERPT]

Title: Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity

Authors: Chen Y, Roberts K, Nakamura T, Wilson D, et al.

Abstract: Background: Irritable bowel syndrome (IBS) affects 10-15% of the global population, but its etiology remains unclear. Gut microbiome alterations have been implicated, yet functional consequences are understudied. We investigated short-chain fatty acid (SCFA) production in IBS patients versus healthy controls.

Methods: We recruited 45 IBS patients (Rome IV criteria) and 40 age- and sex-matched healthy controls. Fecal samples were analyzed using 16S rRNA gene sequencing (V4 region, Illumina MiSeq) and gas chromatography for SCFA quantification. Symptom severity was assessed using the IBS Severity Scoring System (IBS-SSS).

Results: IBS patients showed significantly reduced fecal butyrate (p=0.003) and propionate (p=0.02) compared to controls, while acetate levels were similar. Butyrate concentration negatively correlated with IBS-SSS scores (r=-0.42, p=0.004). Patients with IBS showed depletion of Faecalibacterium prausnitzii and Roseburia species, both known butyrate producers. No significant differences were observed in alpha diversity metrics (Shannon, observed ASVs).

Discussion: Our findings suggest that reduced SCFA production, particularly butyrate, may contribute to IBS symptoms. The correlation with symptom severity supports a functional role for these metabolites. Limitations include the cross-sectional design, which cannot establish causality, and recruitment from a single clinical center. Future longitudinal studies and intervention trials targeting SCFA production are warranted.

Relevance aspect: how microbial metabolites affect gut health in my mouse models

Task: Summarize this paper using the following structure.

1. **Citation**: Format as: Authors (Year). Title. Journal.

2. **Central Finding**: One to two sentences stating the main result or conclusion. Be specific about what was found, not just what was studied.

3. **Research Question/Hypothesis**: What question did the authors set out to answer?

4. **Methods Overview**:
   - Study system/organism
   - Key techniques or approaches
   - Sample size and design (if applicable)

5. **Key Results**: Three to five bullet points of specific findings. Include effect sizes or quantitative results where available.

6. **Limitations**: What limitations do the authors acknowledge? What limitations are apparent but not discussed?

7. **Open Questions**: What questions remain unanswered? What would logical next steps be?

8. **Relevance to My Work**: How might this paper inform how microbial metabolites affect gut health in my mouse models?

Constraints:
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported

Output format: Use the numbered structure above with headers in bold.
````

## Model Output
````
# Literature Note Summary

---

**1. Citation**
Chen Y, Roberts K, Nakamura T, Wilson D, et al. (Year not provided in text). Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity. *Journal not provided in text.*

---

**2. Central Finding**
IBS patients showed significantly reduced fecal butyrate and propionate concentrations compared to healthy controls, and butyrate levels negatively correlated with symptom severity scores. The authors interpret this as suggesting a functional role for reduced SCFA production in IBS symptoms, though the cross-sectional design does not support a causal claim.

---

**3. Research Question/Hypothesis**
The authors set out to investigate whether SCFA production differs between IBS patients and healthy controls, and whether any differences relate to symptom severity. The broader motivation was to characterize functional consequences of gut microbiome alterations in IBS, which the authors note are understudied relative to compositional changes.

---

**4. Methods Overview**

- **Study system/organism:** Human clinical study; adult IBS patients diagnosed by Rome IV criteria and age- and sex-matched healthy controls
- **Key techniques or approaches:**
  - 16S rRNA gene sequencing (V4 region, Illumina MiSeq) for microbiome composition
  - Gas chromatography for fecal SCFA quantification
  - IBS Severity Scoring System (IBS-SSS) for symptom assessment
- **Sample size and design:** 45 IBS patients and 40 healthy controls; cross-sectional design with a single fecal sample collection timepoint (implied by cross-sectional description)

---

**5. Key Results**

- Fecal butyrate was significantly reduced in IBS patients compared to controls (p = 0.003); effect size not reported
- Fecal propionate was significantly reduced in IBS patients compared to controls (p = 0.02); effect size not reported
- Acetate levels did not differ significantly between groups
- Butyrate concentration negatively correlated with IBS-SSS symptom severity scores (r = −0.42, p = 0.004), indicating that lower butyrate was associated with more severe symptoms
- IBS patients showed depletion of *Faecalibacterium prausnitzii* and *Roseburia* species relative to controls; no quantitative effect sizes reported for these taxa
- Alpha diversity (Shannon index, observed ASVs) did not differ significantly between groups

---

**6. Limitations**

**Acknowledged by authors:**
- Cross-sectional design prevents causal inference; it cannot be determined whether reduced SCFA production contributes to IBS or results from it
- Single clinical center recruitment, which may limit generalizability

**Apparent but not discussed by authors:**
- Effect sizes for most comparisons (beyond the butyrate-IBS-SSS correlation) are not reported, making it difficult to assess clinical or biological magnitude
- Publication year and journal are absent from the provided text, limiting full citation
- No dietary data are mentioned; diet is a primary driver of SCFA production and represents a major unmeasured confound
- The mechanism linking reduced butyrate or propionate to specific IBS symptoms is not established by this data
- 16S rRNA sequencing identifies taxa but does not directly measure functional capacity; the link between *F. prausnitzii*/*Roseburia* depletion and observed SCFA reductions is inferred, not demonstrated
- IBS is a heterogeneous condition; subtype breakdown (IBS-C, IBS-D, IBS-M) is not reported, which could obscure subgroup differences
- Single fecal sample per participant may not capture intra-individual variability in SCFA production

---

**7. Open Questions**

*Remaining unanswered based on this paper:*
- Does restoring SCFA production (e.g., through dietary fiber, prebiotics, or probiotic supplementation) reduce IBS symptom severity?
- Is reduced SCFA production a cause, consequence, or correlate of IBS pathophysiology?
- Do findings differ across IBS subtypes?
- What dietary patterns characterize the IBS patients in this cohort, and do they account for SCFA differences?
- Are propionate reductions independently associated with symptom severity, or does this track with butyrate?

*Logical next steps suggested by the authors:*
- Longitudinal studies to track SCFA changes over time
- Intervention trials targeting SCFA production

---

**8. Relevance to My Work**
*How this may inform microbial metabolite effects on gut health in mouse models:*

This paper provides human correlational evidence that butyrate and propionate reductions are associated with gut dysfunction (IBS symptoms), with butyrate showing a moderate negative correlation with symptom severity (r = −0.42). For your mouse model work, this suggests several potentially relevant considerations based solely on what this paper reports:

- **Butyrate as a functional readout:** The correlation between butyrate and symptom severity supports using fecal butyrate quantification (as done here via gas chromatography) as a functional metric alongside compositional sequencing in your models
- **Targeted taxa:** Depletion of *F. prausnitzii* and *Roseburia* was associated with reduced butyrate in this human cohort; if your mouse models show similar compositional shifts, SCFA measurement would be a logical functional follow-up
- **Acetate as a contrast:** The specificity of the finding to butyrate and propionate—with acetate unaffected—suggests that not all SCFAs respond equivalently, which may be relevant when designing metabolite profiling in your experiments
- **Caution on translation:** This is a cross-sectional human study; the authors themselves cannot establish causality, so direct translation to mechanistic mouse work would require experimental manipulation rather than correlation

> ⚠️ *Note: Year and journal are missing from the provided text and should be confirmed before filing this citation.*
````

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
